1Fujimori K,Covell DG Fletcher JE et al.Modeling analysis of the global and microscopic distribution of immunoglobulin G,F(ab')2 and in tumors Cancer Res[J].1989,49:5656.
2Sung C,Youle RJ,Dedrick Rl,Pharmacokinetic analysis of immunotoxin uptake in solid tumors:role of plasma kinetics,capillary permeability,and binding[J].Cancer Res 1990,50:7382.
3Clay B.Siegall,Vijay K,Chaudyary et al.Functional analysis of domains Ⅱ,Ib,and Ⅲ of pseudomonas exotoxin[J].J Biol.Chem 1989.264:14256.
4Kamata NK,Chida K,Rikimaru M,Horikoshi S,e tal.Growth-inhibitory effects of epidermal growth factor and overexpression of its receptor on human squamous cell carcinomas in culture[J].Cancer Res,1986,46:1648.
5Gullick WJ,et al.Prevalence of aberrant expression of the epidermalgrowth-factor receptor in human cancers Brit[J].Med.Bull.1991,47:87.
6YOSHIOKA Y, TSUTSUMI Y, NAKAGAWA S, et al. Recent progress on tumor missile therapy and tumor vascular targeting therapy as a new approach[J]. Curr Vase Pharmacol, 2004,2(3) : 259 -270.
7FONSATI'I E, ALTOMONTE M, ARSLAN P, et al. Endoglin ( CD105 ) : A Target for Anti-angiogenetic Cancer Therapy [ J ]. Current Drug Targets, 2003, 4(4) :291 -296.
8BEATTY J D. lmmunotherapy of colorectal cancer[J]. Cancer, 1992,70(5 ) : 1425 - 1433.
9BAKER R D, HOWL J, NICHOLL I D. A sychnological cell penetrating peptide mimic of p21WAF1/CIP1 is pro-apoptogenic [J]. Peptides, 2007, 28(4): 731 -740.
10CHAUHAN A, TIKOO A, KAPUR A K, et al . The Taming of the Cell Penetrating Domain of the HIV Tat : Myths and Realities [J]. J Control Release,2007, 117(2) : 148 - 162.
